Investor's Business Daily on MSN

Xenon smashes its previous record high on 'unprecedented' results. Is a buyout next?

Xenon Pharmaceuticals stock launched Monday, hitting a record high, on "unprecedented" results for its seizure drug.
Nature

J&J buys Intra-Cellular Therapies for US$14.6 billion, expanding its neuroscience portfolio

Johnson & Johnson will pay US$14.6 billion to acquire Intra-Cellular Therapies. The deal provides J&J with an FDA-approved atypical antipsychotic as well as a pipeline of therapies for diseases of the ...
ascopubs.org

Intra/intertumoral heterogeneity assessed by blood-based next generation sequencing (NGS) to predict inferior survival outcome compared to intratumoral heterogeneity assessed ...

Efficacy and safety of durvalumab plus tremelimumab versus standard chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis of phase III randomized controlled trials.
pv magazine International

NREL researchers quantify UV-induced degradation levels in TOPCon solar cells

Researchers at NREL found that UV exposure can cause significant, partly non-recoverable degradation in TOPCon solar cells, with strong cell-to-cell and intra-cell variability linked to passivation ...